Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Narcolepsy Therapeutics Market, by Type
1.4.2 Europe Narcolepsy Therapeutics Market, by Product
1.4.3 Europe Narcolepsy Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Narcolepsy Therapeutics Market by Type
3.1 Europe Narcolepsy with Cataplexy Market by Country
3.2 Europe Narcolepsy Without Cataplexy Market by Country
3.3 Europe Secondary Narcolepsy Market by Country
Chapter 4. Europe Narcolepsy Therapeutics Market by Product
4.1 Europe Sodium Oxybate Market by Country
4.2 Europe Selective Serotonin Reuptake Inhibitor Market by Country
4.3 Europe Central Nervous System Stimulants Market by Country
4.4 Europe Tricyclic Antidepressants Market by Country
4.5 Europe Others Market by Country
Chapter 5. Europe Narcolepsy Therapeutics Market by Country
5.1 Germany Narcolepsy Therapeutics Market
5.1.1 Germany Narcolepsy Therapeutics Market by Type
5.1.2 Germany Narcolepsy Therapeutics Market by Product
5.2 UK Narcolepsy Therapeutics Market
5.2.1 UK Narcolepsy Therapeutics Market by Type
5.2.2 UK Narcolepsy Therapeutics Market by Product
5.3 France Narcolepsy Therapeutics Market
5.3.1 France Narcolepsy Therapeutics Market by Type
5.3.2 France Narcolepsy Therapeutics Market by Product
5.4 Russia Narcolepsy Therapeutics Market
5.4.1 Russia Narcolepsy Therapeutics Market by Type
5.4.2 Russia Narcolepsy Therapeutics Market by Product
5.5 Spain Narcolepsy Therapeutics Market
5.5.1 Spain Narcolepsy Therapeutics Market by Type
5.5.2 Spain Narcolepsy Therapeutics Market by Product
5.6 Italy Narcolepsy Therapeutics Market
5.6.1 Italy Narcolepsy Therapeutics Market by Type
5.6.2 Italy Narcolepsy Therapeutics Market by Product
5.7 Rest of Europe Narcolepsy Therapeutics Market
5.7.1 Rest of Europe Narcolepsy Therapeutics Market by Type
5.7.2 Rest of Europe Narcolepsy Therapeutics Market by Product
Chapter 6. Company Profiles
6.1 Jazz Pharmaceuticals plc
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Approvals and Trials:
6.2 Shionogi & Co., Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Research & Development Expenses
6.3 Teva Pharmaceutical Industries Ltd.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expenses
6.4 Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional & Segmental Analysis
6.4.4 Research & Development Expense
6.5 Bioprojet
6.5.1 Company Overview
6.5.2 Recent strategies and developments:
6.5.2.1 Partnerships, Collaborations, and Agreements:
6.6 Takeda Pharmaceutical Company Limited
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.7 Ligand Pharmaceuticals, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.8 Graymark Healthcare, Inc.
6.8.1 Company Overview
Unique Offerings 
